A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) [without IMPD-Q] - AIO-TRK-0624
Latest Information Update: 18 Nov 2025
At a glance
- Drugs Tarlatamab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPACE-T
Most Recent Events
- 18 Nov 2025 New trial record